AE	Adverse event
CC-0/1	Complete or near-complete cytoreduction (no visible disease/residual disease < 2.5 mm)
CRS	Cytoreductive surgery
DFS	Disease-free survival
GnP	Gemcitabine plus nab-paclitaxel
HIPEC	Hyperthermic intraperitoneal chemotherapy
IP	Intraperitoneal
LRR	Locoregional recurrence
mOS	Median overall survival
NIPEC	Normothermic intraperitoneal chemotherapy
IP-PTX/NIPEC-PTX	Intraperitoneal paclitaxel
OR	Operating room
OS	Overall survival
PCI	Peritoneal carcinomatosis index
PD	Progressive disease
PDAC	Pancreatic ductal adenocarcinoma
PFS	Progression-free survival
PIPAC	Pressurized intraperitoneal aerosol chemotherapy
PM	Peritoneal metastases
PRGS	Peritoneal Regression Grading Score
RCT	Randomized controlled trial
TME	Tumor microenvironment